In addition, similar to the treatment with CAFR-CM, the treatment with IL8 successfully activated the NF-κB pathway in the tumor cells, and adding anti-IL8 antibodies attenuated the effect of CAFR1-CM and CAFR2-CM (Figs. 4C and S5A). This evidence concerns the gene CXCL8 and neoplasm.